Home LiteratureArticle Details
PMID: 6849767 Published · ppublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't

Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine.

British journal of clinical pharmacology ·Vol. 15 ·No. 3 ·1983-03-00 ·Pages 317-21

Eichelbaum M, Bertilsson L, Säwe J

Abstract

Thirty-five healthy subjects who had been classified as extensive or poor metabolizers of both sparteine and debrisoquine were given a single oral dose of antipyrine. Saliva concentration of antipyrine and urinary excretion of its three major oxidation metabolites were measured. All the parameters of antipyrine metabolism which were estimated had similar distributions in both the 28 EM and 7 PM genetic phenotypes defined by the metabolism of sparteine and debrisoquine. The clearance of antipyrine by the formation of 4-hydroxy-antipyrine and 3-hydroxy-antipyrine respectively were closely correlated (r = 0.83, P less than 0.001) and both were significantly higher in smokers than in non-smokers. Demethylation of antipyrine also seemed to be influenced by smoking, but not to a statistically significant extent. These findings confirm the influence of the environmental factor of smoking in antipyrine oxidative biotransformations.

MeSH Terms
Adult Antipyrine/metabolism Debrisoquin/metabolism Female Humans Isoquinolines/metabolism Kinetics Male Middle Aged Polymorphism, Genetic Saliva/analysis Smoking Sparteine/metabolism
Chemicals
Isoquinolines Sparteine Antipyrine Debrisoquin
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Eichelbaum M
Bertilsson L
Säwe J
References (28)
28 references, click to expand
  1. Genetic control of drug levels in man: antipyrine.
    Science. 1968 Jul 5;161(3836):72-3 PMID: 5690279
  2. Pharmacokinetics and metabolism of antipyrine (phenazone) after intravenous and oral administration.
    Arzneimittelforschung. 1982;32(5):575-8 PMID: 7201837
  3. Factors influencing antipyrine elimination.
    Br J Clin Pharmacol. 1977 Jun;4(3):261-5 PMID: 332216
  4. Polymorphic hydroxylation of Debrisoquine in man.
    Lancet. 1977 Sep 17;2(8038):584-6 PMID: 71400
  5. Genetic and environmental factors affecting drug disposition in man.
    Clin Pharmacol Ther. 1977 Nov;22(5 Pt 2):659-79 PMID: 334437
  6. The antipyrine test in clinical pharmacology: conceptions and misconceptions.
    Clin Pharmacol Ther. 1979 Sep;26(3):275-86 PMID: 111889
  7. Polymorphisms of oxidation at carbon centers of drugs and their clinical significance.
    Drug Metab Rev. 1979;9(2):301-17 PMID: 158499
  8. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.
    Eur J Clin Pharmacol. 1979 Sep;16(3):183-7 PMID: 499318
  9. Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers.
    Br J Clin Pharmacol. 1979 Dec;8(6):529-37 PMID: 533575
  10. Deficient metabolism of debrisoquine and sparteine.
    Clin Pharmacol Ther. 1980 Apr;27(4):547-9 PMID: 7357813
  11. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.
    Eur J Clin Pharmacol. 1980 Feb;17(2):153-5 PMID: 7371707
  12. Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man.
    Life Sci. 1980 Nov 3;27(18):1673-7 PMID: 7442467
  13. Toxicological implications of polymorphic drug metabolism.
    Ciba Found Symp. 1980;76:219-44 PMID: 6906263
  14. Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation.
    Clin Pharmacol Ther. 1981 Apr;29(4):493-7 PMID: 7471615
  15. Phenformin-induced lacticacidosis associated with impaired debrisoquine hydroxylation.
    Lancet. 1981 Apr 11;1(8224):837-8 PMID: 6111700
  16. Hydroxylation of debrisoquine in patients with lacticacidosis after phenformin.
    Lancet. 1981 May 16;1(8229):1098-9 PMID: 6112461
  17. E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation.
    Clin Pharmacol Ther. 1981 Aug;30(2):189-93 PMID: 7249504
  18. Influence of the genetically controlled deficiency in debrisoquine hydroxylation on antipyrine metabolite formation.
    Pharmacology. 1981;22(6):349-58 PMID: 7267701
  19. Genetic variation in rates of antipyrine metabolite formation: a study in uninduced twins.
    Proc Natl Acad Sci U S A. 1981 Aug;78(8):5193-6 PMID: 6946467
  20. HPLC determination of antipyrine metabolites.
    Pharmacology. 1981;23(4):192-202 PMID: 7323136
  21. Family study of antipyrine clearance.
    Br Med J (Clin Res Ed). 1982 Jan 16;284(6310):150-2 PMID: 6799075
  22. Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.
    Clin Pharmacol Ther. 1982 Feb;31(2):184-6 PMID: 7056024
  23. Differential effects of enzyme induction on antipyrine metabolite formation.
    Br J Clin Pharmacol. 1982 Mar;13(3):379-86 PMID: 7059438
  24. Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man.
    Br J Clin Pharmacol. 1981 Dec;12(6):771-7 PMID: 7340879
  25. Defective oxidation of drugs: pharmacokinetic and therapeutic implications.
    Clin Pharmacokinet. 1982 Jan-Feb;7(1):1-22 PMID: 7042170
  26. Differential induction of antipyrine metabolism by rifampicin.
    Eur J Clin Pharmacol. 1981;21(2):155-60 PMID: 7341283
  27. Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time.
    Eur J Clin Pharmacol. 1982;21(5):433-41 PMID: 7075648
  28. Antipyrine metabolism in man: influence of age, alcohol, caffeine, and smoking.
    Clin Pharmacol Ther. 1975 Oct;18(4):425-32 PMID: 1164824
Article Info
Journal
British journal of clinical pharmacology
Abbr.
Br J Clin Pharmacol
ISSN
0306-5251
Published
1983-03-00
Pages
317-21
Language
English
Region
England
NLM ID
7503323
PMCID
PMC1427783
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com